Related Experiment Video
Updated: May 25, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Assessing the risks of current COVID-19 challenge trials systematically
1Institute for Health, School of Public Health, and Department of Philosophy, Rutgers University. 112 Paterson Street, Room 400, New Brunswick, NJ 08901, USA.
None:
A large international collaboration has started a series of SARS-CoV-2 (COVID) human challenge trials (HCTs). However, critics of previously proposed COVID HCTs deemed them unethical for posing excessive risks to participants. These concerns raise the need to evaluate the risks of the planned COVID HCTs. Systematic analysis reveals that, although the risks of these trials would be high in some populations, they are clearly acceptable for eligible individuals and may even qualify as "minimal" for them. This conclusion is important for evaluating the planned COVID HCTs and highlights the importance of assessing the risks of later COVID HCTs and HCTs in future pandemics systematically.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Hazard Ratio
For example, in a clinical trial...
Controls in Experiments
Steps in Outbreak Investigation

